Thus, promoting PAK6-LRRK2 interaction through stabilizing molecules or CRIB-mimicking compounds rather than increasing the amount of PAK6 cellular concentration should be considered as a route for future therapeutic developments in stratified LRRK2-PD patients. This evidence concerns the gene LRRK2 and Parkinson disease.